Last reviewed · How we verify
Measles-Rubella (MR) Vaccine
The MR vaccine stimulates the immune system to produce antibodies and cellular immunity against measles and rubella viruses through live attenuated viral antigens.
The MR vaccine stimulates the immune system to produce antibodies and cellular immunity against measles and rubella viruses through live attenuated viral antigens. Used for Prevention of measles, Prevention of rubella.
At a glance
| Generic name | Measles-Rubella (MR) Vaccine |
|---|---|
| Sponsor | PT Bio Farma |
| Drug class | Live attenuated viral vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains weakened (attenuated) strains of measles and rubella viruses that replicate in vaccinated individuals without causing disease. This triggers both humoral (antibody) and cell-mediated immune responses, providing long-term protection against natural infection with these viruses. The vaccine prevents measles and rubella infection and their associated complications including encephalitis, congenital rubella syndrome, and other serious sequelae.
Approved indications
- Prevention of measles
- Prevention of rubella
Common side effects
- Fever
- Rash
- Local injection site reactions (pain, erythema, swelling)
- Arthralgia/arthritis
- Lymphadenopathy
Key clinical trials
- Strengthening HPV Immunization Through EPI Leveraged Delivery (PHASE2)
- A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants (PHASE2)
- A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants (PHASE1)
- Infant Malaria Vaccine Schedule Optimization (PHASE2)
- Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of Age (PHASE4)
- A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age (PHASE2)
- Non-interference Study of MR and Yellow Fever Vaccines Among Bangladeshi Infants Aged 9-12 Months (PHASE3)
- A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Measles-Rubella (MR) Vaccine CI brief — competitive landscape report
- Measles-Rubella (MR) Vaccine updates RSS · CI watch RSS
- PT Bio Farma portfolio CI